Navigation Links
Stiefel Laboratories Appoints Two New Members to Board of Directors
Date:9/21/2007

Private equity investor The Blackstone Group now represented on company's

board

CORAL GABLES, Fla., Sept. 21 /PRNewswire/ -- Stiefel Laboratories, Inc. today announced the appointment of two new members to the company's board of directors. The appointments include a representative of the private equity firm The Blackstone Group, which recently became a minority-share investor in the company.

Joining the board are Lodewijk J.R. de Vink, a founding member of Blackstone Healthcare Partners LLP (BHP), and Jeffrey S. Thompson, chief operating officer for Stiefel Laboratories.

Charles W. Stiefel is president, chief executive officer and chairman of Stiefel Laboratories.

"I am pleased to welcome Jeff and Lodewijk to the board at this exciting time," Stiefel said. "Their appointments strengthen our board and thus our company. I am confident they will complement the team as our company continues to grow."

Blackstone's $500 million investment in Stiefel Laboratories, a deal which closed August 10, includes the right to designate one member on the company's board of directors.

Lodewijk de Vink has more than 40 years experience in the pharmaceutical and healthcare industries. In addition to working for such companies as Schering-Plough, Credit Suisse First Boston and Warner-Lambert Company as chairman and CEO, de Vink has been a consultant with Blackstone since 2003 and currently sits on several boards including Roche and Alcon.

"An important aspect of our relationship with Blackstone," Stiefel said, "is the ability to leverage its resources and experience. I look forward to working with Lodewijk not only because of his warm persona, but because of the unparalleled experience he brings to the board."

Jeffrey S. Thompson, COO, Stiefel Laboratories, also joins the board. Thompson, who is responsible for operations on a global level including corporate administration, facilities management, supply chain and technical operations, information technology, human resources, legal, quality and corporate compliance, plays a key role in the integration of the company's U.S. and international business. Previously, Thompson served as the President of Glades Pharmaceuticals, a wholly-owned subsidiary of Stiefel.

"Throughout his career at Stiefel Laboratories, Jeff has impressed us with his energy, enthusiasm and vast knowledge of the pharmaceutical industry," Stiefel said. "He was an instrumental part of the recent Connetics acquisition, spending several months living in Palo Alto, Calif. and serving as the on-site integration leader. His management skills have contributed to the organization's growth and success internationally and we know he will be a valuable addition to the board."

The Stiefel Laboratories board of directors also includes: William D. (Bill) Humphries, chief commercial officer; Richard MacKay, president, Stiefel Canada, Inc. and vice chairman of the board; Gabriel McGlynn, senior vice president of EURASIA; Brent Stiefel, executive vice president, global corporate development and product portfolio; Catherine Stiefel, certified public accountant, mergers & acquisitions; and Todd Stiefel, executive vice president, global strategy.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; Soriatane(R) (acitretin) capsules; Verdeso(TM) (desonide) Foam, 0.05%; Brevoxyl(R) Creamy Wash (benzoyl peroxide, 4% or 8%) packaged in the convenient new Brevoxyl Acne Wash Kit; Oilatum(R); Physiogel(R); Stieprox(R) (ciclopirox olamine); and Sarna(R). Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit http://www.stiefel.com.


'/>"/>
SOURCE Stiefel Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. Distance-Learning Remote Laboratories using LabVIEW
3. States are the best laboratories for healthcare reform
4. Scientific Protein Laboratories Acquired by New York firm
5. Sharon Ethanol appoints operations director
6. Kyron appoints former AMA chairman to board
7. Brady appoints GE efficiency expert as CTO
8. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
9. Johnson Controls appoints Roell to head EOC
10. SecurePipe appoints two senior execs
11. Milwaukees PointOne appoints new president and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
(Date:2/8/2016)... 2016 --> ... innovation-driven oncology company developing next generation cancer therapeutics ... announced that chairman emeritus of Tata Sons Limited, ... company as part of the first close of ... Navam Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas J. Todorow has joined ... President for Corporate Services and the Chief Financial Officer at The Children’s Hospital ... Treasury, Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP ...
Breaking Biology Technology:
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):